Breast Cancer
Online ISSN : 1880-4233
Print ISSN : 1340-6868
ISSN-L : 1340-6868
Original Articles
Tolerability and Safety of Classic Cyclophosphamide, Methotrexate, and Fluorouracil Treatment in Japanese Patients with Early Breast Cancer
Keiichiro TadaYoshinori ItoShunji TakahashiKohtaro IijimaYumi MiyagiSeiichiro NishimuraKaoru TakahashiMasujiro MakitaTakuji IwaseMasataka YoshimotoFujio Kasumi
著者情報
ジャーナル フリー

2006 年 13 巻 3 号 p. 279-283

詳細
抄録
Background: Few reports have addressed the feasibility and safety of classic Cyclophosphamide, Methotrexate, and Fluorouracil (CMF) therapy in Japanese female breast cancer patients.
Methods: Twenty-four Japanese patients who received classic CMF, identical to the originally described treatment regimen were studied in terms of treatment dose, treatment delay, and toxicity.
Results: Classic CMF was not discontinued in any of the cases. The median delay in treatment was 14 days, and the mean administered dose of cyclophsphamide was 98.2% of the planned dose. None of the patients suffered severe side-effects such as febrile neutropenia; however, in 22 patients in whom the effect of CMF on hair loss could be assessed, 7 (31.8%) had to wear hats or wigs.
Conclusions: Classic CMF is a feasible and safe regimen in Japanese breast cancer patients. In Japan, this regimen is still available for some specific groups of early breast cancer patients.
著者関連情報

この記事は最新の被引用情報を取得できません。

© 2006 by The Japanese Breast Cancer Society
前の記事 次の記事
feedback
Top